Partnering opportunity

Innovative target therapy for melanoma treatment

Summary

Italian biotech SME, focused on translational oncology, discovered an innovative technology for re-engineering natural products and created a novel, organic new small molecule to be exploited for melanoma treatment. The new drug is of natural origin and comprises characterized scaffolds and pharmacophores with anti-proliferative, tumor-selective actions. Biotechnology and pharmaceutical industry are sought for license or financial agreements.

Partner sought

- Type of partner sought: Biotechnology and/or pharmaceutical company and/or SMEs - Specific area of activity of the partner: healthcare, pre-clinical and clinical trials, ex vivo & vitro research, tests on 1) resistant cells from human biopsies, 2) combinations with existing treatments, 3) long-term efficacy and 4) identification of target and all mechanism of action. -Types of cooperation agreement: 1) financial with option of own manufacturing capacities; 2) license in this case the partner is expected to purchase rights for the use of the patent-protected solution 3) Financing for scale-up 4) Knowledge in terms of capacity and accreditation to carry out pre-clinical studies.

Description

The Italian biotech company, specialized in basic and translational research for the development of innovative technologies and drugs, has successfully performed discovery, lead identification and optimization and proof-of-concept, of a New Molecular Entity (NME) to be exploited for melanoma treatment and to be applied for the cure of patients. The new drug discovered is an organic, oral target therapy for melanoma. It consists of an innovative technology from re-engineering natural products in a novel, organic small molecule. In vitro tests have demonstrated the drug efficacy in halting melanoma cell proliferation, and it is tumor-selective, showing a limited effect on non-cancer cells. It may be synergic with other existing treatments and may have the capacity to penetrate human biological barriers. It could represent a solution for the biologic drug regards pharmacological treatment for melanoma and other skin cancers. This biologic drug has been re-engineered from the natural compounds flavonoids. Successfully tested in vitro has been reached with translational methodologies. The application & customer segments are: -- Treatment of adult patients with metastatic, not surgically removable melanoma not responding to immunotherapies or target therapies; -- Treatment of naïve adult patients with metastatic, not surgically removable melanoma in combination with immunotherapies; -- Treatment of adult patients with early stage melanoma at risk of unexpected progression after surgical treatment or earlier in treatment. Biotechnology and/or pharmaceutical company or SMEs are sought for license or financial agreement. The area of activity of the partner searched are: healthcare, pre-clinical and clinical trials, ex vivo & vitro research, tests

Advantages and innovations

The main advantages are: --drop of cancer cell proliferation; --limited effect on non-cancer cells; --utilized for all patient groups / skin cancers. The bio drug is simple to manufacture and manage, and compatible with other available treatments. In addition the biological drug could be prescribed and commercialized through the Hospital channel, Oncologists and Dermatologists as main prescribers. The innovative aspect is the that the biologic drug has been re-engineered from flavonoids (natural compounds).

Development stage

Field tested/evaluated

Intellectual Property Rights (IPR)

Patents granted,Exclusive Rights


Register your interest

How it works

  • Tell us about yourself
  • We’ll discuss with you
  • We put the right partners in touch

EEN help you find the right partner, rather than you going it alone.

Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.

These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.

Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.

?What value does EEN add?
This is your pitch: remember to include your unique selling points (USP) and why someone would want to do business with you
Tell us why you are a good fit for this opportunity, and why you think you're the right people for this partnership
If there's anything additional, or commercially sensitive you'd like to know about this opportunity, please let us know

When you entered your email address above, we emailed you a code to verify you're human and have access to that account.

?What's this?

What next?

To finish up, we just need some extra details about you and your company